Literature DB >> 32228001

Update: Sexually transmitted infections, active component, U.S. Armed Forces, 2011-2019.

.   

Abstract

This report summarizes incidence rates of the 5 most common sexually transmitted infections (STIs) among active component service members of the U.S. Armed Forces during 2011-2019. Infections with chlamydia were the most common, followed in decreasing order of frequency by infections with genital human papillomavirus (HPV), gonorrhea, genital herpes simplex virus (HSV), and syphilis. Compared to men, women had higher rates of all STIs except for syphilis. In general, compared to their respective counterparts, younger service members, non-Hispanic black service members, soldiers, and enlisted members had higher incidence rates of STIs. The incidence of chlamydia and gonorrhea generally increased among both male and female service members in the latter half of the surveillance period but may have begun to level off or decrease in 2019. Rates of syphilis increased for male service members through 2018 but decreased slightly in 2019; the rate among female service members increased from 2011 to 2014 but leveled off through 2018 before increasing in 2019. The incidence of genital HPV generally decreased among both male and female service member but rose slightly among women in 2019; HSV incidence decreased among both male and female service members. Similarities to and differences from the findings of the last MSMR update on STIs are discussed.

Entities:  

Mesh:

Year:  2020        PMID: 32228001

Source DB:  PubMed          Journal:  MSMR        ISSN: 2152-8217


  1 in total

1.  Feasibility, acceptability, and short-term impact of a brief sexually transmitted infection intervention targeting U.S. Military personnel and family members.

Authors:  Anjali Kunz; Amber Moodley; Donn J Colby; Michele Soltis; Wesley Robb-McGrath; Alexandra Fairchok; Paul Faestel; Amanda Jungels; Alexis A Bender; Edwin Kamau; Gina Wingood; Ralph DiClemente; Paul Scott
Journal:  BMC Public Health       Date:  2022-04-02       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.